Top Notch Delivery

[Prince Aboubakar]

TopNotch Delivery Service offers delivery, receiving, inspections, hanging, and over 12,000 square feet of climate controlled storage in Delray Beach, Florida. We offer full inspections & provide daily receiving reports.

Top-Notch Delivery Service is a family owned and operated company with over 20 years of quality service & experience in the interior design industry. We specialize in working directly with the interior designer.

All UK orders valued at 30 and over are shipped FREE to UK Post Codes from our Hull based studio, in the East Riding of Yorkshire, England, within 10 working days. A delivery charge of 2.00 is applied to orders below 30.00.

The tracking number issued by Royal Mail 1st Class provides confirmation that it has been posted and again when it has been delivered. If there is no update on the Royal Mail tracking system this means that it is still with the Royal Mail.

Shop online and browse our wide variety of products. All orders must have a valid State or Federal picture ID uploaded with it. For Medical Patients it must be a valid Medical Marijuana Card. For others a State or Federal picture id can be used. The person receiving the order must match the picture on the ID submitted with the order.

When a delivery order is placed a team member will be in contact with you through the WeedMaps text system to verify your order before sending it to processing. Once verified with all the delivery details the order will be sent to fulfillment for packaging and checkout.

When the order is ready to be delivered, we will send out a text with the amount of the order. When the driver is ready to leave the store you will receive another text letting you know they will be leaving on their route. Please have as close to the actual amount as you can. We only accept cash payments.

When the driver arrives, please try to maintain the required distance from them. They will hand you your order, collect payment, then have you sign the drivers app, and the required Nevada State Delivery Manifest. Note - Drivers do not carry change.

When shopping online make sure you are in the curbside menu area. Once your order is placed you will receive a text stating your order is being processed. Once your order is ready a text will be sent out with your total, and a message saying it's time to pick up your order. Please do not show up to the store until you have received the text telling you to come down.

Top Notch is focused on providing the best customer experience in the cannabis industry. We are working daily to make our curbside pick-up and delivery the best in Nevada. Go ahead and browse our wide variety of amazing cannabis products. When you are ready to order select either curbside pick-up or delivery and receive personalized updates throughout your ordering process.

The site is secure.

The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often linked to aggressive forms of cancer, evading standard treatment highlighting Notch as an exciting therapeutic target. Notch is in principle "druggable" by γ-secretase inhibitors (GSIs), inhibitory peptides and antibodies, but clinical use of Notch inhibitors is restricted by severe side effects and there is a demand for alternative cancer-targeted therapy. Here, we present a novel approach, using imagable mesoporous silica nanoparticles (MSNPs) as vehicles for targeted delivery of GSIs to block Notch signaling. Drug-loaded particles conjugated to targeting ligands induced cell-specific inhibition of Notch activity in vitro and exhibited enhanced tumor retainment with significantly improved Notch inhibition and therapeutic outcome in vivo. Oral administration of GSI-MSNPs controlled Notch activity in intestinal stem cells further supporting the in vivo applicability of MSNPs for GSI delivery. MSNPs showed tumor accumulation and targeting after systemic administration. MSNPs were biocompatible, and particles not retained within the tumors, were degraded and eliminated mainly by renal excretion. The data highlights MSNPs as an attractive platform for targeted drug delivery of anticancer drugs with otherwise restricted clinical application, and as interesting constituents in the quest for more refined Notch therapies.

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Fractures, congenital defects, and malignancies of the cranial, axial, and appendicular skeleton present a common challenge; however, current therapies aimed at promoting bone regeneration have significant shortcomings. By the age of 50, 50% of women and 20% of men will have suffered a fracture.1 Up to 12% of tibia shaft fractures experience nonunion,2 and approximately 25% of bone allografts to repair the resection of malignant bone tumors fail.3 Indeed, the direct medical costs of osteoporosis-related fractures alone in the United States exceeds $20 billion annually.4 The total societal burden of these injuries, which includes healthcare utilization, reduced quality/quantity of life and opiate abuse, will continue to rise with ageing and the prevalence of comorbidities.5 The bone morphogenetic proteins (BMPs) were once championed as versatile skeletal growth factors and the answer to the bone healing problem, but the widespread off-label clinical use of BMPs contributed to an increasingly poor safety record and a pronounced drop in their utilization.6 Thus, there remains a major unmet public health need for alternative and/or complimentary bone-anabolic factors that can promote healing of high-risk fractures or volumetric bone defects.

Genetic deletion of Jag1 in mice is embryonic lethal,10 and canonical RBPjκ-mediated Notch signaling regulates the activity of skeletal stem cells during development.11 Notch inhibition in limb bud mesenchyme (Prx1-Cre;Psen1f/fPsen2-/- or Prx1-Cre;Notch1-/fNotch2f/f) causes stunting of the skeleton with an expanded cartilaginous growth plate, a decrease in marrow stem cell number and a reduction in osteoblast marker gene expression in vitro.12 Deletion of the dominant ligand, Jag1 (Prx1-Cre;Jag1f/f), dysregulates the osteochondral progenitor cell pool and produces compartment-specific phenotypes including femoral trabecular osteopenia in adulthood.13 Notch2 deletion in early osteoblasts (Runx2-Cre;Notch2f/f) increases bone volume (BV) in selected regions.14 In committed osteoblasts, Notch1 overactivation (Col1a1-Cre;N1ICDTg) causes hypertrophic intramedullary osteosclerosis, and Notch inactivation (Col1a1-Cre;.Psen1f/fPsen2-/-) results in vertebral and appendicular osteopenia.15

Taken together, there is likely a spatiotemporal switch that occurs midway through the continuum of osteoblast differentiation. Early activation of Notch drives progenitor cell proliferation and inhibits entrance into the early osteochondral phase, whereas mid-to-late activation of Notch drives osteoblast differentiation and promotes the anabolic activity of committed osteoblasts. Activating Notch in primed, post-injury mesenchyme represents a potential targeted strategy to increase bone formation.

Mammalian Notch ligands require physical association with a cell/object in order to effectively signal: soluble Notch ligands are competitive antagonists to the pathway.20 Jag1 can be immobilized onto a scaffold or carrier to induce osteoblast differentiation, and we have previously demonstrated feasibility of this approach in vitro using human primary cell lines.21,22 The goal of this study was to further define the regulatory role of Notch signaling in osteoblast differentiation and intramembranous bone healing in vivo, and to explore the therapeutic utility of Jag1 to promote bone anabolism. Our hypothesis was that Jag1 would promote osteoblastogenesis of mesenchymal progenitor cells and drive bone regeneration in experimentally induced bone defects in rodents. Herein, we demonstrate that Jag1 is a safe and effective local therapeutic for bone repair. Disruption of Jag1 during bone formation reduces bone healing, and delivery of Jag1 using clinically applicable collagen sponges significantly enhances bone healing without excess ectopic bone.

There is an urgent need to develop new therapeutics for bone repair. While BMPs have proven to be potent tools and remain the clinical standard for promoting bone regeneration, over the past 5 years it has become clear that BMPs are not universally beneficial. Potential adverse effects of BMPs include inflammation, adipogenesis, ectopic/hypertrophic bone, radiculopathy and death.23 Additionally, BMPs can induce osteoclastogenesis in individuals with osteoporosis, exacerbating loss of mineral content and disqualifying a significant patient population. We demonstrate that the Notch signaling ligand Jag1 is required for maximal intramembranous bone regeneration and that delivery of Jag1 can promote new bone healing in both rats and mice.

Having identified a positive regulatory role of Jag1 in adult bone healing, we sought to therapeutically deliver Jag1 protein to the site of a calvarial defect in mice, which heals by intramembranous ossification. Notch (DLL4) gain-of-function has been proposed as a therapeutic paradigm for muscle healing,27 but recombinant Notch ligand has, until now, never been used to drive regeneration. Agarose Protein G beads were previously used to deliver Jag1 in vitro,22 so a similar approach was adopted using 5μm-diameter biodegradable PLGA microcarrier beads (rigid substrate for Jag1) embedded in Gelfoam (osteoconductive scaffold). This approach resulted in significantly greater defect coverage and BV versus microcarrier-laden vehicle by CT 42-days post-defect. The positive control, BMP2, delivered at an approximately equimolar concentration, produced a complex boney mass, with retained Gelfoam and adipocyte-laden marrow, protruding well above the surrounding parietal bones. The C-Jag1 group had 59.9% of the regenerated BV of the GF-BMP2 group, but importantly, the new bone remained in the plane of the defect, and was qualitatively more similar to the native cranial bone.

3a8082e126